Pfizer Inc. said a global late-stage trial evaluating its Covid-19 vaccine is almost fully enrolled with participants, but the drugmaker hasn’t conducted the first review of whether it works safely.
Pfizer’s Phase 3 trial seeking 44,000 volunteers needs fewer than 2,000 people to be fully enrolled, the company said Tuesday while announcing third-quarter earnings. The New York-based company also said that nearly 36,000 people in the trial received their second injection of either the two-dose vaccine or placebo.
Pfizer’s…
This post first appeared on wsj.com
